Hepatorenal syndrome: A dreaded complication of end-stage liver disease

American Journal of Gastroenterology

Volumn 100, Issue 2, 2005, Pages 460-467

  Cárdenas, Andrés ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; MIDODRINE; NORADRENALIN; OCTREOTIDE; PENTOXIFYLLINE; TERLIPRESSIN; VASOCONSTRICTOR AGENT;

ALBUMIN DIALYSIS; ALCOHOL LIVER DISEASE; BACTERIAL PERITONITIS; DIALYSIS; DISEASE ASSOCIATION; HEPATORENAL SYNDROME; HUMAN; KIDNEY BLOOD VESSEL; KIDNEY FAILURE; KIDNEY PERFUSION; LIFE EXPECTANCY; LIVER FAILURE; PATHOGENESIS; PATHOPHYSIOLOGY; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SPLANCHNIC BLOOD FLOW; VASOCONSTRICTION; KIDNEY CIRCULATION;

HEPATORENAL SYNDROME; HUMANS; PROGNOSIS; RENAL CIRCULATION; VASOCONSTRICTION;

EID: 13944260896     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.40952.x     Document Type: Review

References (49)

1. Arroyo V, Ginès P, Gerbes A, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-76.
2. Ginès P, Cárdenas A, Arroyo V, et al. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-54.
3. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-48.
4. Moore K. Renal failure in acute liver failure. Eur J Gastroenterol Hepatol 1999;11:967-75.
5. Ginès A, Escorsell A, Ginès P, et al. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 1993;105:229-36.
6. Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 1970;49:175-85.
7. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
8. Martin PY, Ginès P, Schrier RW. Role of nitric oxide as mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998;339:533-41.
9. Dudley FJ, Esler MD. The sympathetic nervous system in cirrhosis. In: Arroyo V, Ginès P, Rodés J, Schrier RW, eds. Ascites and renal dysfunction in Liver disease. Malden (MA): Blackwell Science, 1999:198-219.
10. Arroyo V, Clària J, Saló J, et al. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 1994;14:44-58.
11. Moore K. Arachidonic acid metabolites and the kidney in cirrhosis. In: Arroyo V, Ginès P, Rodés J, Schrier RW, eds. Ascites and renal dysfunction in liver disease. Malden (MA): Blackwell Science, 1999:249-72.
12. Cárdenas A, Uriz J, Ginés P, et al. Hepatorenal syndrome. Liver Transplantation 2000;4(Suppl 1):S63-S71.
13. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-501.
14. Ruiz-del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-8.
15. Lee SS. Cardiac dysfunction in spontaneous bacterial peritonitis: A manifestation of cirrhotic cardiomyopathy? Hepatology 2003;38:1089-91.
16. Caregaro L, Menon F, Angeli P, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994;154:201-5.
17. Planas R, Ginès P, Arroyo V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology 1990;99:1736-44.
18. Cárdenas A, Ginès P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis. Incidence, clinical course, predictive factors and short-term prognosis. Hepatology 2001;34:671-6.
19. Ginès P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet 2003;362:1819-27.
20. Roy L, Legault L, Pomier-Layrargues G. Glomerular filtration rate measurement in cirrhotic patients with renal failure. Clin Nephrol 1998;50:342-6.
21. Dudley FJ, Kanel GC, Wood JL, et al. Hepatorenal syndrome without sodium retention. Hepatology 1986;6:248-59.
22. Cárdenas A, Ginès P. Pathogenesis and treatment of dilutional hyponatremia in cirrhosis. In: Arroyo V, Forns X, Garcia-Pagan JC, Rodes J, eds. Progress in the treatment of liver diseases. Barcelona: Ars Medica, 2003:31-42.
23. Alessandria C, Venon WD, Marzano A, et al. Renal failure in cirrhotic patients: Role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002;14:1363-8.
24. Brensing KA, Textor J, Perz J, et al. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: A phase II study. Gut 2000;47:288-95.
25. Arroyo V, Bataller R, Guevara M. Treatment of hepatorenal syndrome in cirrhosis. In: Arroyo V, Ginès P, Rodés J, Schrier RW, eds. Ascites and renal dysfunction in liver disease. Pathogenesis, diagnosis, and treatment. Maiden (MA): Blackwell Science, 1999:492-510.
26. Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 1996;347:1842-3.
27. Holt S, Goodier D, Marley R, et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999;353:294-5.
28. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41.
29. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999;30:870-5.
30. Uriz J, Gines P, Cárdenas A, et al. Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-8.
31. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. Gastroenterology 2002;122:923-30.
32. Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome. Results of a prospective, non-randomized study. Hepatology 2002;36:941-8.
33. Mulkay JP, Louis H, Donckier V, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: A pilot study. Acta Gastroenterol Belg 2001;64:15-9.
34. Halimi C, Bonnard P, Bernard B, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: Results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002;14:153-8.
35. Colle I, Durand F, Pessione F, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: A retrospective analysis. J Gastroenterol Hepatol 2002;17:882-8.
36. Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003;18:152-6.
37. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-97.
38. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64.
39. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenaline and albumin in patients with type 1 hepatorenal syndrome: A pilot study. Hepatology 2002;36:374-80.
40. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004;40:140-6.
41. Boyer TD. Transjugular intrahepatic portosystemic shunt: Current status. Gastroenterology 2003;124:1700-10.
42. Guevara M, Gines P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology 1998;28:416-22.
43. Ginès P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839-47.
44. Ochs A, Rössle M, Haag K, et al. The transjugular intrahepatic portosystemic stent shunt procedure for refractory ascites. N Engl J Med 1995;332:1192-7.
45. Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000;342:1701-7.
46. Sanyal AJ, Genning C, Reddy RK, et al. Nastra Group. The North American Study of Treatment for Refractory Ascites (NASTRA). Gastroenterology 2003;124:634-41.
47. Mitzer SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-86.
48. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70.
49. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;5:403-9.